Safety of cabergoline in the management of pituitary prolactin-induced symptoms with patients treated with atypical neuroleptics

Current Drug Safety

Volumn 7, Issue 2, 2012, Pages 92-98

  Coronas, Ramón ^a   Cobo, Jesús ^a   Giménez Palop, Olga ^a   Ortega, Emilio ^a   Márquez, Manel ^b  

^a Centre de Salut Mental   (Spain)

^b PARC SANITARI SANT JOAN DE DÉU   (Spain)

Author keywords

Atypical antipsychotics; Cabergoline; Dopamine; Hyperprolactinaemia; Hypothalamus; Pituitary gland; Prolactin; Schizophrenia

Indexed keywords

AMISULPRIDE; CABERGOLINE; CLOZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE;

ADULT; AMENORRHEA; ARTICLE; CLINICAL ARTICLE; DRUG SAFETY; EJACULATION; FEMALE; FOLLOW UP; GALACTORRHEA; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; IMPOTENCE; LIBIDO; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84870312402     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488612802715753     Document Type: Article

References (82)

1. Moller I, Thomas A, Geyer H, Schanzer W, Thevis M. Synthesis, characterisation, and mass spectrometric detection of a pegylated EPO-mimetic peptide for sports drug testing purposes. Rapid Commun Mass Spectrom 2011; 25(15): 2115-23.
2. Jelkmann W, Lundby C. Blood doping and its detection. Blood 2011; 118(9): 2395-404.
3. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355(20): 2071-84.
4. Aher SM, Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006; 3: CD004865.
5. Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006; 3: CD004863.
6. Abhary S, Burdon KP, Casson RJ, Goggin M, Petrovsky NP, Craig JE. Association between erythropoietin gene polymorphisms and diabetic retinopathy. Arch Ophthalmol 2010; 128(1): 102-6.
7. Tong Z, Yang Z, Patel S, et al. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci U S A 2008; 105(19): 6998-7003.
8. Rastmanesh R. Possibility of enhanced risk of retinal neovascularization in repeated blood donors: blood donation and retinal alteration. Int J Gen Med 2011; 4: 647-56.
9. Shortt AJ, Howell K, O'Brien C, McLoughlin P. Chronic systemic hypoxia causes intra-retinal angiogenesis. J Anat 2004; 205(5): 349-56.
10. Wangsa-Wirawan ND, Linsenmeier RA. Retinal oxygen: fundamental and clinical aspects. Arch Ophthalmol 2003; 121(4): 547-557.
11. Woorons X, Mollard P, Pichon A, Duvallet A, Richalet JP, Lamberto C. Prolonged expiration down to residual volume leads to severe arterial hypoxemia in athletes during submaximal exercise. Respir Physiol Neurobiol 2007; 158(1): 75-82.
12. Guenette JA, Romer LM, Querido JS, et al. Sex differences in exercise-induced diaphragmatic fatigue in endurance-trained athletes. J Appl Physiol 2010; 109(1): 35-46.
13. Powers SK, Dodd S, Lawler J, et al. Incidence of exercise induced hypoxemia in elite endurance athletes at sea level. Eur J Appl Physiol Occup Physiol 1988; 58(3): 298-302.
14. Richards JC, McKenzie DC, Warburton DE, Road JD, Sheel AW. Prevalence of exercise-induced arterial hypoxemia in healthy women. Med Sci Sports Exerc 2004; 36(9): 1514-21.
15. Rice AJ, Scroop GC, Gore CJ, et al. Exercise-induced hypoxaemia in highly trained cyclists at 40% peak oxygen uptake. Eur J Appl Physiol Occup Physiol 1999; 79(4): 353-9.
16. Roberts D, Smith DJ. Erythropoietin concentration and arterial haemoglobin saturation with supramaximal exercise. J Sports Sci 1999; 17(6): 485-93.
17. Goodnough LT, Brittenham GM. Limitations of the erythropoietic response to serial phlebotomy: implications for autologous blood donor programs. J Lab Clin Med 1990; 115(1): 28-35.
18. Christoulas K, Karamouzis M, Mandroukas K. "Living high-training low" vs "living high-training high": erythropoietic responses and performance of adolescent cross-country skiers. J Sports Med Phys Fitness 2011; 51(1): 74-81.
19. Clark SA, Quod MJ, Clark MA, Martin DT, Saunders PU, Gore CJ. Time course of haemoglobin mass during 21 days live high:train low simulated altitude. Eur J Appl Physiol 2009; 106(3): 399-406.
20. Gore CJ, Rodriguez FA, Truijens MJ, et al. Increased serum erythropoietin but not red cell production after 4 wk of intermittent hypobaric hypoxia (4,000-5,500 m). J Appl Physiol 2006; 101(5): 1386-93.
21. Heinicke K, Heinicke I, Schmidt W, Wolfarth B. A three-week traditional altitude training increases hemoglobin mass and red cell volume in elite biathlon athletes. Int J Sports Med 2005; 26(5): 350-5.
22. Mounier R, Pialoux V, Cayre A, et al. Leukocyte's Hif-1 expression and training-induced erythropoietic response in swimmers. Med Sci Sports Exerc 2006; 38(8): 1410-17.
23. Ricci G, Masotti M, De P, V, Vedovato M, Zanotti G. Effects of exercise on haematologic parameters, serum iron, serum ferritin, red cell 2,3-diphosphoglycerate and creatine contents, and serum erythropoietin in long-distance runners during basal training. Acta Haematol 1988; 80(2): 95-98.
24. Robinson Y, Cristancho E, Boning D. Intravascular hemolysis and mean red blood cell age in athletes. Med Sci Sports Exerc 2006; 38(3): 480-3.
25. Roecker L, Kowoll R, Fraszl W, et al. Observation of serum erythropoietin concentrations in female athletes for up to eight days after a marathon run. Clin Lab 2006; 52(9-10): 511-3.
26. Wehrlin JP, Zuest P, Hallen J, Marti B. Live high-train low for 24 days increases hemoglobin mass and red cell volume in elite endurance athletes. J Appl Physiol 2006; 100(6): 1938-45.
27. Arjamaa O, Nikinmaa M. Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp Eye Res 2006; 83(3): 473-83.
28. Yu DY, Cringle SJ. Retinal degeneration and local oxygen metabolism. Exp Eye Res 2005; 80(6): 745-51.
29. Cheng XW, Kuzuya M, Kim W, Song H, Hu L, Inoue A et al. Exercise training stimulates ischemia-induced neovascularization via phosphatidylinositol 3-kinase/Akt-dependent hypoxia-induced factor-1 alpha reactivation in mice of advanced age. Circulation 2010; 122(7): 707-16.
30. Lutty GA, McLeod DS, Merges C, Diggs A, Plouet J. Localization of vascular endothelial growth factor in human retina and choroid. Arch Ophthalmol 1996; 114(8): 971-7.
31. Kim SY, Mocanu C, McLeod DS, Bhutto IA, Merges C, Eid M et al. Expression of pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in sickle cell retina and choroid. Exp Eye Res 2003; 77(4): 433-45.
32. Amin RH, Frank RN, Kennedy A, Eliott D, Puklin JE, Abrams GW. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 1997; 38(1): 36-47.
33. Xiao Q, Zeng S, Ling S, Lv M. Up-regulation of HIF-1alpha and VEGF expression by elevated glucose concentration and hypoxia in cultured human retinal pigment epithelial cells. J Huazhong Univ Sci Technolog Med Sci 2006; 26(4): 463-5.
34. Takagi H, Watanabe D, Suzuma K, et al. Novel role of erythropoietin in proliferative diabetic retinopathy. Diabetes Res Clin Pract 2007; 77 (Suppl 1): S62-S64.
35. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005; 353(8): 782-92.
36. Aher S, Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006; 3: CD004868.
37. Brown MS, Baron AE, France EK, Hamman RF. Association between higher cumulative doses of recombinant erythropoietin and risk for retinopathy of prematurity. J AAPOS 2006; 10(2): 143-49.
38. Brown MS, Eichorst D, Lala-Black B, Gonzalez R. Higher cumulative doses of erythropoietin and developmental outcomes in preterm infants. Pediatrics 2009; 124(4): e681-e687.
39. Fortes Filho JB, Eckert GU, Procianoy L, Barros CK, Procianoy RS. Incidence and risk factors for retinopathy of prematurity in very low and in extremely low birth weight infants in a unit-based approach in southern Brazil. Eye (Lond) 2009; 23(1): 25-30.
40. Romagnoli C, Zecca E, Gallini F, Girlando P, Zuppa AA. Do recombinant human erythropoietin and iron supplementation increase the risk of retinopathy of prematurity? Eur J Pediatr 2000; 159(8): 627-8.
41. Sato T, Kusaka S, Shimojo H, Fujikado T. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology 2009; 116(9): 1599-1603.
42. Garcia-Ramirez M, Hernandez C, Simo R. Expression of erythropoietin and its receptor in the human retina: a comparative study of diabetic and nondiabetic subjects. Diabetes Care 2008; 31(6): 1189-94.
43. Chen J, Smith LE. A double-edged sword: erythropoietin eyed in retinopathy of prematurity. J AAPOS 2008; 12(3): 221-2.
44. Frank RN. On the pathogenesis of diabetic retinopathy. A 1990 update. Ophthalmology 1991; 98(5): 586-93.
45. Lagreze WA, Feltgen N, Bach M, Jehle T. Feasibility of intravitreal erythropoietin injections in humans. Br J Ophthalmol 2009; 93(12): 1667-71.
46. Hernandez C, Fonollosa A, Garcia-Ramirez M, et al. Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema. Diabetes Care 2006; 29(9): 2028-33.
47. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85(3): 221-8.
48. Kalka C, Tehrani H, Laudenberg B, et al. VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease. Ann Thorac Surg 2000; 70(3): 829-34.
49. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med 2000; 342(9): 626-33.
50. Shintani S, Murohara T, Ikeda H, et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001; 103(23): 2776-9.
51. Lee IG, Chae SL, Kim JC. Involvement of circulating endothelial progenitor cells and vasculogenic factors in the pathogenesis of diabetic retinopathy. Eye (Lond) 2006; 20(5): 546-52.
52. Lip PL, Belgore F, Blann AD, Hope-Ross MW, Gibson JM, Lip GY. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment. Invest Ophthalmol Vis Sci 2000; 41(8): 2115-9.
53. Lip PL, Chatterjee S, Caine GJ, et al. Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade. Br J Ophthalmol 2004; 88(12): 1543-6.
54. Rex TS, Allocca M, Domenici L, et al. Systemic but not intraocular Epo gene transfer protects the retina from light-and genetic-induced degeneration. Mol Ther 2004; 10(5): 855-61.
55. Otani A, Dorrell MI, Kinder K, Moreno SK, Nusinowitz S, Banin E et al. Rescue of retinal degeneration by intravitreally injected adult bone marrow-derived lineage-negative hematopoietic stem cells. J Clin Invest 2004; 114(6): 765-774.
56. Junk AK, Mammis A, Savitz SI, Singh M, Roth S, Malhotra S et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A 2002; 99(16): 10659-10664.
57. Sasahara M, Otani A, Oishi A, et al. Activation of bone marrowderived microglia promotes photoreceptor survival in inherited retinal degeneration. Am J Pathol 2008; 172(6): 1693-1703.
58. Mowat FM, Gonzalez F, Luhmann UF, et al. Endogenous erythropoietin protects neuroretinal function in ischemic retinopathy. Am J Pathol 2012; 180(4): 1726-39.
59. McVicar CM, Hamilton R, Colhoun LM, et al. Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy. Diabetes 2011; 60(11): 2995-3005.
60. Westenbrink BD, Oeseburg H, Kleijn L, et al. Erythropoietin stimulates normal endothelial progenitor cell-mediated endothelial turnover, but attributes to neovascularization only in the presence of local ischemia. Cardiovasc Drugs Ther 2008; 22(4): 265-74.
61. Ballin A, Bilker-Reich A, Arbel E, Davidovitz Y, Kohelet D. Erythropoietin, given enterally, stimulates erythropoiesis in premature infants. Lancet 1999; 353(9167): 1849.
62. Britton JR, Christensen RD. Enteral administration of recombinant erythropoietin to preterm infants. J Perinatol 1995; 15(4): 281-283.
63. Pasha YZ, Hmadpour-Kacho M, Hajiahmadi M, Hosseini MB. Enteral erythropoietin increases plasma erythropoietin level in preterm infants: a randomized controlled trial. Indian Pediatr 2008; 45(1): 25-28.
64. Frederiksen BL, Caye-Thomasen P, Lund SP, et al. Does erythropoietin augment noise induced hearing loss? Hear Res 2007; 223(1-2): 129-37.
65. Abraham PA, Macres MG. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J Am Soc Nephrol 1991; 2(4): 927-36.
66. Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW. Hypertension following erythropoietin therapy in anemic hemodialysis patients. Am J Hypertens 1990; 3(12 Pt 1): 947-955.
67. Clyne N, Egberg N, Lins LE. Effects of hemodialysis and longterm erythropoietin treatment on protein C, and on free and total protein S. Thromb Res 1995; 80(2): 161-8.
68. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362(9392): 1255-60.
69. Ishikawa A, Suzuki K, Fujita K. A preventive effect of a selective endothelin-A receptor antagonist, S-0139, on the erythropoietininduced reduction of the renal cortical blood flow. Urol Res 1999; 27(5): 312-4.
70. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005; 104(12): 2822-9.
71. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003; 4(8): 459-60.
72. Rosenzweig MQ, Bender CM, Lucke JP, Yasko JM, Brufsky AM. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage 2004; 27(2): 185-90.
73. Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000; 95(9): 2983-9.
74. Tassies D, Reverter JC, Cases A, Calls J, Escolar G, Ordinas A. Effect of recombinant human erythropoietin treatment on circulating reticulated platelets in uremic patients: association with early improvement in platelet function. Am J Hematol 1998; 59(2): 105-9.
75. Tokish JM, Kocher MS, Hawkins RJ. Ergogenic aids: a review of basic science, performance, side effects, and status in sports. Am J Sports Med 2004; 32(6): 1543-53.
76. Wolf RF, Peng J, Friese P, Gilmore LS, Burstein SA, Dale GL. Erythropoietin administration increases production and reactivity of platelets in dogs. Thromb Haemost 1997; 78(6): 1505-9.
77. Bonsignore MR, Morici G, Riccioni R, et al. Hemopoietic and angiogenetic progenitors in healthy athletes: different responses to endurance and maximal exercise. J Appl Physiol 2010; 109(1): 60-67.
78. Kraus RM, Stallings HW III, Yeager RC, Gavin TP. Circulating plasma VEGF response to exercise in sedentary and endurancetrained men. J Appl Physiol 2004; 96(4): 1445-50.
79. Pialoux V, Brugniaux JV, Fellmann N, et al. Oxidative stress and HIF-1 alpha modulate hypoxic ventilatory responses after hypoxic training on athletes. Respir Physiol Neurobiol 2009; 167(2): 217-20.
80. Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB. A hypothesis: can erythropoietin administration affect the severity of retinopathy in diabetic patients with renal failure? Am J Med Sci 2007; 334(4): 260-4.
81. Neogi T, Chen C, Chaisson C, Hunter D, Zhang Y. Short-Term effects of caffeinated beverage intake on risk of recurrent gout attacks. Arthritis Rheum 20102; 62(10): 1362.
82. Zhang Y, Chen C, Hunter D, Chaisson C, Choi H, Neogi T. Cherry consumption and risk of recurrent gout attacks. Arthritis Rheum 2010; 62(10): 1366.